Ballatori Enzo, Roila Fausto
Medical Statistics Unit, Dept. of Internal Medicine and Public Health, University, P. Tommasi 2, L'Aquila, Italy.
Health Qual Life Outcomes. 2003 Sep 17;1:46. doi: 10.1186/1477-7525-1-46.
It is commonly claimed that the nausea and vomiting accompanying cytotoxic chemotherapy have a negative impact on health-related quality of life. While this may seem self-evident, until a few years ago there was little empirical data demonstrating that the failure to control postchemotherapy emesis affects aspects of quality of life. In spite of their limitations, several observational studies showed that nausea and vomiting associated with chemotherapy induced a decrease in health-related quality of life with respect to patients without nausea and vomiting. This has also been demonstrated after the adjustment for health-related quality of life before chemotherapy that is an important prognostic factor of chemotherapy-induced nausea and vomiting. Furthermore, one study suggests that the optimal time of assessment of quality of life to evaluate the impact of chemotherapy-induced nausea and vomiting is day 4 if a 3-day recall period is used or day 8 when the recall period is 7 days. In double-blind studies the efficacy, tolerability and impact on quality of life of the 5-HT3 receptor antagonists was superior with respect to metoclopramide, alizapride and prochlorperazine. Similar results have been achieved with the combination of ondansetron with dexamethasone, the standard treatment for the prevention of acute emesis induced by moderately emetogenic chemotherapy, with respect to the metoclopramide plus dexamethasone combination. Instead, in another double-blind study, in patients submitted to moderately emetogenic chemotherapy, a 5-HT3 antagonist did not seem to significantly increase complete protection from delayed emesis and the patients' quality of life with respect to dexamethasone alone. In conclusion, the evaluation of quality of life in randomized trials comparing different antiemetic drugs for the prevention of chemotherapy-induced nausea and vomiting can add important information useful for the choice of the optimal antiemetic treatment.
人们普遍认为,细胞毒性化疗伴随的恶心和呕吐会对健康相关生活质量产生负面影响。虽然这似乎不言而喻,但直到几年前,几乎没有实证数据表明化疗后呕吐控制不佳会影响生活质量的各个方面。尽管存在局限性,但多项观察性研究表明,与化疗相关的恶心和呕吐会导致健康相关生活质量相对于无恶心和呕吐的患者有所下降。在对化疗前的健康相关生活质量进行调整后也证实了这一点,化疗前的健康相关生活质量是化疗引起恶心和呕吐的重要预后因素。此外,一项研究表明,如果采用3天回忆期,评估化疗引起的恶心和呕吐对生活质量影响的最佳时间是第4天;如果回忆期为7天,则是第8天。在双盲研究中,5-HT3受体拮抗剂在疗效、耐受性和对生活质量的影响方面优于胃复安、阿立必利和丙氯拉嗪。对于预防中度致吐性化疗引起的急性呕吐的标准治疗方案——昂丹司琼与地塞米松联合使用,相对于胃复安加地塞米松联合使用,也取得了类似的结果。相反,在另一项双盲研究中,对于接受中度致吐性化疗的患者,一种5-HT3拮抗剂相对于单独使用地塞米松,似乎并没有显著提高对延迟性呕吐的完全预防效果和患者的生活质量。总之,在比较不同止吐药物预防化疗引起的恶心和呕吐的随机试验中评估生活质量,可以为选择最佳止吐治疗提供重要的有用信息。